Amylin’s SymlinPen To Launch In December
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."
You may also be interested in...
Amylin CEO: Firm Can Do Better With Byetta
Diabetes drug so far has failed to catch on with primary-care docs.
Amylin CEO: Firm Can Do Better With Byetta
Diabetes drug so far has failed to catch on with primary-care docs.
Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.